Related Experiment Video

Updated: Jul 12, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

[The most important clinical interactions among medicines used in cardiologic practice]

Tomasz Mikulski1

  • 1Oddzial Internistyczno-Kardiologiczny i Regionalny Ośrodek Toksykologii Klinicznej Samodzielny Publiczny Szpital Wojewódzki im. Jana Bozego w Lublinie.

Przeglad Lekarski
|August 30, 2007
PubMed

Insights

This review covers crucial drug interactions in cardiovascular patients, focusing on cytochrome P450 metabolism. Understanding these interactions is vital for managing polypharmacy and preventing adverse drug events in cardiology.

Area of Science:

  • Pharmacology
  • Cardiology
  • Drug Metabolism

Context:

  • Cardiovascular patients often have multiple comorbidities and are prescribed numerous medications.
  • Polypharmacy increases the risk of adverse drug events due to drug-drug interactions.
  • Cytochrome P450 enzymes play a significant role in the metabolism of many cardiovascular drugs.

Purpose:

  • To review clinically significant drug interactions relevant to cardiovascular practice.
  • To highlight interactions involving cytochrome P450-dependent drug metabolism.
  • To discuss both beneficial and detrimental drug interactions in cardiology.

Summary:

  • The article reviews key drug interactions in cardiovascular patients, with a focus on those involving cytochrome P450 metabolism.
  • It addresses the heightened risk of drug interactions in elderly patients with multiple conditions and medications.
  • Both advantageous and disadvantageous interactions are detailed for medications used in cardiology.

Impact:

  • Provides essential information for cardiologists to optimize medication regimens.
  • Aims to improve patient safety by minimizing adverse drug reactions.
  • Facilitates better management of cardiovascular diseases through informed prescribing practices.

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...